KRM Ayurveda Ltd

KRM Ayurveda operates with a debt-to-equity ratio of 1.31, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.66, suggesting it can cover short-term obligations but with limited buffer. Free cash flow of INR 84.17 million provides some flexibility, though operating cash flow is negative at INR -0.29 million, signaling potential operational inefficiencies. Profitability metrics show a return on equity (ROE) of 50.67% and a return on assets (ROA) of 18.11%, both significantly above the industry median for Ayurvedic and herbal pharmaceuticals. These figures suggest strong capital efficiency and asset utilization. Gross profit of INR 670.52 million represents 87.6% of revenue, indicating a high-margin business model. The company's revenue is concentrated in a single business segment focused on Ayurvedic and herbal products, with no disclosed geographic diversification beyond India. This concentration increases exposure to domestic regulatory and economic shifts. No material international revenue is reported, and no segment breakdown is available in the latest filings. Revenue growth over the past year is not disclosed, but the company's free cash flow and operating income suggest a stable, if not growing, business. The capital expenditure of INR -47.24 million indicates a reduction in investment, which may signal a shift in strategic focus or a response to cash flow constraints. Risk factors include a negative net cash position after subtracting total debt, which could limit financial flexibility. The dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. No recent equity issuance or ATM/shelf registration is disclosed in the latest filings. Recent events include the filing of the latest financial snapshot, which shows a stable but cash-constrained balance sheet. No material earnings call transcripts or regulatory filings are available in the current dataset. The company's focus on Ayurvedic and herbal products aligns with growing consumer interest in traditional medicine, but it remains exposed to regulatory scrutiny and raw material price volatility.